Palisade Bio says Phase 1b study shows early clinical, biomarker gains for PALI-2108 in fibrostenotic Crohn’s disease
Bitget2026/09/28 12:50- Palisade Bio flagged new Phase 1b clinical and translational readouts for PALI-2108 ahead of UEG Week 2026 in Barcelona.
- Results will be presented in the future, including an oral talk on fibrostenotic Crohn’s disease on Oct. 18, 2026.
- Data are set to show early endoscopic improvement, biomarker shifts consistent with PDE4 target engagement, favorable safety, and gut-targeted exposure.
- Separate presentations are expected to indicate rapid clinical response in ulcerative colitis and progress on a biomarker to predict responders.
- PALI-2108 is moving into Phase 2 development in ulcerative colitis and Crohn’s disease as a once-daily oral therapy candidate.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Only twice in history! S&P 500 equal-weight index is expected to record seven consecutive weeks of decline this week
The S&P 500 Equal Weight Index is expected to fall for a seventh consecutive week. If this downward trend continues through Friday, it will mark only the third time in history that the index has experienced seven straight weeks of decline.
Trump “bites” Powell, demanding his resignation from the Federal Reserve Board, citing severe cost overruns in headquarters renovation.
U.S. President Trump on Wednesday called for former Federal Reserve Chairman Powell to resign from his position as a Fed governor, following an inspector general report on the Federal Reserve headquarters renovation project, which highlighted a series of management issues that led to significant cost overruns.
Gladstone Investment Closes Acquisition of Extrude Hone
Crypto prices
More
